Functional in vitro characterization of SLCO1B1 variants and simulation of the clinical pharmacokinetic impact of impaired OATP1B1 function

Show full item record



Permalink

http://hdl.handle.net/10138/346696

Citation

Kiander , W , Sjostedt , N , Manninen , R , Jaakkonen , L , Vellonen , K-S , Neuvonen , M , Niemi , M , Auriola , S & Kidron , H 2022 , ' Functional in vitro characterization of SLCO1B1 variants and simulation of the clinical pharmacokinetic impact of impaired OATP1B1 function ' , European Journal of Pharmaceutical Sciences , vol. 176 , 106246 . https://doi.org/10.1016/j.ejps.2022.106246

Title: Functional in vitro characterization of SLCO1B1 variants and simulation of the clinical pharmacokinetic impact of impaired OATP1B1 function
Author: Kiander, Wilma; Sjostedt, Noora; Manninen, Riikka; Jaakkonen, Liina; Vellonen, Kati-Sisko; Neuvonen, Mikko; Niemi, Mikko; Auriola, Seppo; Kidron, Heidi
Contributor organization: Division of Pharmaceutical Biosciences
Drug Delivery Unit
Department of Clinical Pharmacology
HUSLAB
Medicum
Drug Research Program
Date: 2022-09-01
Language: eng
Number of pages: 9
Belongs to series: European Journal of Pharmaceutical Sciences
ISSN: 0928-0987
DOI: https://doi.org/10.1016/j.ejps.2022.106246
URI: http://hdl.handle.net/10138/346696
Abstract: Organic Anion Transporting Polypeptide 1B1 is important to the hepatic elimination and distribution of many drugs. If OATP1B1 function is decreased, it can increase plasma exposure of e.g. several statins leading to increased risk of muscle toxicity. First, we examined the impact of three naturally occurring rare variants and the frequent SLCO1B1 c.388A > G variant on in vitro transport activity with cellular uptake assay using two substrates: ', 7'-dichlorofluorescein (DCF) and rosuvastatin. Secondly, LC-MS/MS based quantitative targeted absolute proteomics measured the OATP1B1 protein abundance in crude membrane fractions of HEK293 cells over -expressing these single nucleotide variants. Additionally, we simulated the effect of impaired OATP1B1 function on rosuvastatin pharmacokinetics to estimate the need for genotype-guided dosing. R57Q impaired DCF and rosuvastatin transport significantly yet did not change protein expression considerably, while N130D and N151S did not alter activity but increased protein expression. R253Q did not change protein expression but reduced DCF uptake and increased rosuvastatin Km. Based on pharmacokinetic simulations, doses of 30 mg (with 50% OATP1B1 function) and 20 mg (with 0% OATP1B1 function) result in plasma exposure similar to 40 mg dose (with 100% OATP1B1 function). Therefore dose reductions might be considered to avoid increased plasma exposure caused by function-impairing OATP1B1 genetic variants, such as R57Q.
Subject: Pharmacogenetics
Rosuvastatin
Pharmacokinetics
Simulation
Proteomics
SLCO1B1 POLYMORPHISM
TRANSPORT ACTIVITY
DRUG TRANSPORTERS
HEPATIC-UPTAKE
C SLC21A6
ROSUVASTATIN
EXPRESSION
VARIANTS
QUANTIFICATION
METAANALYSIS
317 Pharmacy
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0928098722001312_main.pdf 2.259Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record